Beyond substance abuse, behavioral addictions are also a major problem in society. We went to addiction-specialist, Awakn Life Sciences to learn more these additional treatment markets.
Mydecine announces a partnership with Combat Stress and King's College London to provide psychoactive-assisted therapy for PTSD.
Novamind announces a CAD$5 million placement with a single institutional investor. Units are priced at CAD$0.40 with a full warrant at CAD$0.50.
Numinus Wellness reports Q1 2022 results, including quarterly revenues of CAD$0.8 million and a gross profit of CAD$50,965.
Eleusis, a private psychedelics company, has announced it is going public via a merger with Silver Spike Acquisition Corp II.
Levitee Labs announces a CAD$3 million private placement with units priced at CAD$0.20 and a full warrant at CAD$0.40.
Numinus announces all regulatory authorization and preparations have been completed for the next stage of MAPS' clinical trial for MDMA-assisted psychotherapy.